Citations

Clear

6 citation(s) found for "Souza, Rhonda".

Response to Rajendra
Shaheen, Nicholas J. , Iyer, Prasad G. , Souza, Rhonda F. , Wani, Sachin , Falk, Gary W. , Yadlapati, Rena , Sauer, Bryan G.

Mayo Clinic

American Journal of Gastroenterology | November 3, 2022 | Volume: 117 | Issue: 11 | Pages: 1881-1882

10.14309/ajg.0000000000002012 | PMID 36327439 Get It

Guideline to Practice: Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline
Shaheen, Nicholas J. , Iyer, Prasad G. , Souza, Rhonda F. , Wani, Sachin , Falk, Gary W.

Mayo Clinic

American Journal of Gastroenterology | April 25, 2022 | Volume: 117 | Issue: 8 | Pages: 1177-1180

10.14309/ajg.0000000000001788 | PMID 35467555 Get It

Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline
Shaheen, Nicholas J. , Iyer, Prasad G. , Souza, Rhonda F. , Sauer, Bryan G. , Wani, Sachin , Falk, Gary W. , Yadlapati, Rena

Mayo Clinic

American Journal of Gastroenterology | March 31, 2022 | Volume: 117 | Issue: 4 | Pages: 559-587

10.14309/ajg.0000000000001680 | PMID 35354777 Get It

Barrett's esophagus (BE) is a common condition associated with chronic gastroesophageal reflux disease. BE is the only known precursor to esophageal adenocarcinoma, a highly lethal cancer with an increasing incidence over the last 5 decades. These revised guidelines implement Grading of Recommendations, Assessment, Development, and Evaluation methodology to propose recommendations for the definition and diagnosis of BE, screening for BE and esophageal adenocarcinoma, surveillance of patients with known BE, and the medical and endoscopic treatment of BE and its associated early neoplasia. Important changes since the previous iteration of this guideline include a broadening of acceptable screening modalities for BE to include nonendoscopic methods, liberalized intervals for surveillance of short-segment BE, and volume criteria for endoscopic therapy centers for BE. We recommend endoscopic eradication therapy for patients with BE and high-grade dysplasia and those with BE and low-grade dysplasia. We propose structured surveillance intervals for patients with dysplastic BE after successful ablation based on the baseline degree of dysplasia. We could not make recommendations regarding chemoprevention or use of biomarkers in routine practice due to insufficient data.
Gastroesophageal Junction Fat Pad Tissue from Obese Patients Impairs Esophageal Epithelial Barrier Function and Disrupts Cell‐to‐Cell Connections
Paris, Sheré , Ekeanyanwu, Rebecca, Davis, Daniel, Whelan, Kelly A. , Iyer, P. K. R., Katzka, David A. , Podgaetz, Eitan , Leeds, Steven G. , Zhang, Xi , Souza, Rhonda, Iyer, Prasad, Ward, Marc A. , Spechler, Stuart Jon

Mayo Clinic

The FASEB Journal | June 10, 2021 | Volume: 35 | Issue: S1 | Pages: No page available

10.1096/fasebj.2021.35.s1.02126 Get It

Introduction Visceral obesity is associated with GERD and, traditionally, it has been assumed that visceral fat predisposes to GERD primarily by increasing intra‐abdominal pressure. However, transmission electron microscopy (TEM) of esophageal biopsies from obese individuals without GERD exhibit dilated intercellular spaces (DIS) and, in earlier studies, we found that substances secreted by mature adipocytes in visceral fat from obese patients impair esophageal epithelial barrier function, induce DIS and reduce transepithelial resistance (TER). There is a fat pad at the gastroesophageal junction (GEJ) that is in intimate contact with the distal esophagus. We now explore whether whole GEJ fat tissue of obese individuals secretes substances that impair esophageal barrier function. Methods We obtained GEJ fat from 3 obese (BMI 46, 60, 74) and 3 non‐obese (BMI 24, 26, 27) patients having foregut surgery. Human esophageal squamous cells were seeded into transwells and grown to confluence for 3 days. On day 4, cells were raised to an air‐liquid interface (ALI) to allow for differentiation, stratification, and esophageal barrier formation. ALI cultures were exposed to conditioned media (CM) from GEJ fat or to control medium beginning at day 4. TER was measured on days 4, 6, and 8 using the EVOM2 Epithelial Volt/Ohm Meter. On day 8, ALI cultures were stained with H&E and Ki‐67 and imaged; barrier permeability was assessed by a biotinylation reagent applied to the ALI surface. TEM of ALIs and of esophageal biopsies from 2 non‐obese and 2 obese patients without GERD were assessed. Results CM from all 3 obese patients significantly reduced TER on days 6 and 8; CM from 2 non‐obese patients did not reduce TER whereas CM from 1 non‐obese patient induced a slight reduction in TER at day 8 (Table 1). Marked DIS were found only in ALI cultures grown with CM from obese patients. In ALIs grown with CM from non‐obese patients, the biotinylation reagent stopped at the superficial layers of esophageal cells. In contrast, the biotinylation reagent diffused through all cell layers in ALIs grown with obese patient CM. Increases in basaloid cells and in Ki‐67 were found in ALIs grown with obese patient CM. TEMs of ALIs grown with non‐obese patient CM demonstrated well‐oriented cell‐cell junctions similar to TEMs of non‐obese patient esophageal biopsies. In contrast, ALIs grown with obese patient CM demonstrated cell‐cell junctional structures that were disorganized, aggregated, and floating within the DIS, similar in appearance to TEMs of the obese patients’ esophageal biopsies. Conclusion Substances produced by GEJ fat of obese patients impair esophageal epithelial barrier integrity, cause basal cell hyperplasia and DIS, and disrupt intercellular connections. These findings in ALI cultures recapitulate abnormalities seen by TEM in esophageal biopsies of obese patients.
Causes, evaluation, and consequences of eosinophilic esophagitis
Chehade, Mirna , Achem, Sami R., Souza, Rhonda F. , Lucendo, Alfredo

Mayo Clinic

Annals of the New York Academy of Sciences | June 6, 2014 | Volume: 1300 | Issue: 1 | Pages: 110-118

10.1111/nyas.12243 | PMID 24117638 Get It

This paper presents commentaries on whether eosinophilic esophagitis is a food allergy; inflammation in the context of eosinophilic esophagitis; whether eosinophilic esophagitis a cause of noncardiac chest pain; the role of endoscopy in the evaluation of eosinophilic esophagitis; and whether response to proton pump inhibitor therapy can distinguish eosinophilic esophagitis from gastroesophageal reflux disease.
Defining esophageal landmarks, gastroesophageal reflux disease, and Barrett's esophagus
DeVault, Kenneth R. , McMahon, Barry P. , Marchese, Michele , Hejazi, Reza , McCallum, Richard W. , Savarino, Vincenzo , Zentilin, Patrizia , Savarino, Edoardo , Thomson, Mike , Souza, Rhonda F. , Donohoe, Claire L. , O’Farrell, Naoimh J. , Reynolds, John V. , DeVault, Kenneth, Çelebi, Altay , Costamagna, Guido , Clarke, John O. , Savarino, Edoardo

Mayo Clinic

Annals of the New York Academy of Sciences | January 6, 2014 | Volume: 1300 | Issue: 1 | Pages: 278-295

10.1111/nyas.12253 | PMID 24117649 Get It

The following paper on gastroesophageal reflux disease (GERD) and Barrett's esophagus (BE) includes commentaries on defining esophageal landmarks; new techniques for evaluating upper esophageal sphincter (UES) tone; differential diagnosis of GERD, BE, and hiatal hernia (HH); the use of high‐resolution manometry for evaluation of reflux; the role of fundic relaxation in reflux; the use of 24‐h esophageal pH–impedance testing in differentiating acid from nonacid reflux and its potential inclusion in future Rome criteria; classification of endoscopic findings in GERD; the search for the cell origin that generates BE; and the relationship between BE, Barrett's carcinoma, and obesity.